Literature DB >> 27865024

Impact of the zero-markup drug policy on hospitalisation expenditure in western rural China: an interrupted time series analysis.

Caijun Yang1,2, Qian Shen1,2, Wenfang Cai1,2, Wenwen Zhu1,2, Zongjie Li1,2, Lina Wu1,2, Yu Fang1,2.   

Abstract

OBJECTIVES: To assess the long-term effects of the introduction of China's zero-markup drug policy on hospitalisation expenditure and hospitalisation expenditures after reimbursement.
METHODS: An interrupted time series was used to evaluate the impact of the zero-markup drug policy on hospitalisation expenditure and hospitalisation expenditure after reimbursement at primary health institutions in Fufeng County of Shaanxi Province, western China. Two regression models were developed. Monthly average hospitalisation expenditure and monthly average hospitalisation expenditure after reimbursement in primary health institutions were analysed covering the period 2009 through to 2013.
RESULTS: For the monthly average hospitalisation expenditure, the increasing trend was slowed down after the introduction of the zero-markup drug policy (coefficient = -16.49, P = 0.009). For the monthly average hospitalisation expenditure after reimbursement, the increasing trend was slowed down after the introduction of the zero-markup drug policy (coefficient = -10.84, P = 0.064), and a significant decrease in the intercept was noted after the second intervention of changes in reimbursement schemes of the new rural cooperative medical insurance (coefficient = -220.64, P < 0.001).
CONCLUSIONS: A statistically significant absolute decrease in the level or trend of monthly average hospitalisation expenditure and monthly average hospitalisation expenditure after reimbursement was detected after the introduction of the zero-markup drug policy in western China. However, hospitalisation expenditure and hospitalisation expenditure after reimbursement were still increasing. More effective policies are needed to prevent these costs from continuing to rise.
© 2016 John Wiley & Sons Ltd.

Keywords:  China; National Essential Medicines Policy; hospitalisation expenditure; interrupted time series analysis; zero-markup drug policy

Mesh:

Substances:

Year:  2016        PMID: 27865024     DOI: 10.1111/tmi.12817

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  9 in total

1.  Views of Pharmacists and Government Representatives Toward the Pilot Chief Pharmacist System in Chinese Hospitals: A Multicenter Exploratory Qualitative Study.

Authors:  Ruomeng Yang; Qian Li; Khezar Hayat; Panpan Zhai; Wenchen Liu; Chen Chen; Amna Saeed; Jie Chang; Pengchao Li; Qianqian Du; Sen Xu; Jun Wen; Yu Fang
Journal:  Front Public Health       Date:  2022-06-15

2.  Impact of China's healthcare price reforms on traditional Chinese medicine public hospitals in Beijing: an interrupted time-series study.

Authors:  Dawei Zhu; Xuefeng Shi; Stephen Nicholas; Qian Bai; Ping He
Journal:  BMJ Open       Date:  2019-08-10       Impact factor: 2.692

3.  Impacts of government supervision on hospitalization costs for inpatients with COPD: An interrupted time series study.

Authors:  Peiyi Li; Zhanqi Duan; Ziwu Zhang; Yunzhen He; Weimin Li
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

4.  Medical costs and hospital utilization for hemophilia A and B urban inpatients in China: a national cross-sectional study.

Authors:  Zhengwei Huang; Stephen Nicholas; Yong Yang; Xiaoping Chen; Elizabeth Maitland; Yong Ma; Xuefeng Shi
Journal:  BMC Health Serv Res       Date:  2022-02-19       Impact factor: 2.655

5.  Impact of the National Reimbursement Drug List Negotiation Policy on Accessibility of Anticancer Drugs in China: An Interrupted Time Series Study.

Authors:  Hong Zhu; Jingmin Zhu; Yingyu Zhou; Linghan Shan; Cui Li; Yu Cui; Zheng Kang; Mingli Jiao; Huan Liu; Lijun Gao; Qunhong Wu; Yanhua Hao
Journal:  Front Public Health       Date:  2022-07-01

6.  Factors that dynamically affect provincial incidences of catastrophic health expenditure among middle-aged and elderly Chinese population-transition of disease financial risk protection from global to local.

Authors:  Xiyu Zhang; Wenqing Miao; Mingli Jiao; Bing Wu; Yongqiang Lai; Qi Xia; Chenxi Zhang; Wanxin Tian; Zhe Song; Linghan Shan; Lingqin Hu; Xinhao Han; Hui Yin; Xiaonan Cheng; Ye Li; Baoguo Shi; Qunhong Wu
Journal:  BMC Geriatr       Date:  2022-09-16       Impact factor: 4.070

7.  Does the leading pharmaceutical reform in China really solve the issue of overly expensive healthcare services? Evidence from an empirical study.

Authors:  Yunzhen He; Guanshen Dou; Qiaoyun Huang; Xinyu Zhang; Yingfeng Ye; Mengcen Qian; Xiaohua Ying
Journal:  PLoS One       Date:  2018-01-16       Impact factor: 3.240

8.  Impacts of the zero mark-up drug policy on hospitalization expenses of COPD inpatients in Sichuan province, western China: an interrupted time series analysis.

Authors:  Junman Wang; Peiyi Li; Jin Wen
Journal:  BMC Health Serv Res       Date:  2020-06-08       Impact factor: 2.655

9.  Impact of the zero-mark-up drug policy on drug-related expenditures and use in public hospitals, 2016-2018: an interrupted time series study in Shaanxi.

Authors:  Kangkang Yan; Caijun Yang; Hongli Zhang; Dan Ye; Shengyuan Liu; Jie Chang; Minghuan Jiang; Mingyue Zhao; Yu Fang
Journal:  BMJ Open       Date:  2020-11-26       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.